Insight Molecular Diagnostics (IMDX) Profit Margin (2020 - 2026)
Insight Molecular Diagnostics (IMDX) profit margin from Mar 31, 2020 to Mar 31, 2026. The current Insight Molecular Diagnostics (IMDX) profit margin is -14300.00%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Profit Margin
Quarterly Profit Margin
Annual Profit Margin change of Insight Molecular Diagnostics (IMDX)
| Year | Profit Margin | Change |
|---|---|---|
| 2025 | -1236.95% | -61.66% |
| 2024 | -3226.60% | +74.22% |
| 2023 | -1852.00% | -75.61% |
| 2022 | -7593.75% | +160.63% |
| 2021 | -2913.64% | +18.76% |
| 2020 | -2453.28% | +102.63% |
| 2020 | -1210.71% | -81.39% |
| 2020 | -6507.14% | -83.16% |
| 2020 | -38650.00% | N/A |
Comparison Insight Molecular Diagnostics (IMDX) profit margin with competitors
Insight Molecular Diagnostics (IMDX) profit margin is -14300.00%.
| Ticker | Name | Profit Margin | Upside |
|---|---|---|---|
| IDXX | Idexx Laboratories Inc | 24.41% | -100.17% |
| VCYT | Veracyte Inc | 20.64% | -100.14% |
| QGEN | Qiagen NV | 20.33% | -100.14% |
| A | Agilent Technologies Inc | 18.47% | -100.13% |
| MTD | Mettler-Toledo International Inc | 17.89% | -100.13% |
| MEDP | Medpace Holdings Inc | 17.53% | -100.12% |
| DHR | Danaher Corp | 17.29% | -100.12% |
| BLLN | Billiontoone Inc - Class A | 16.58% | -100.12% |
| TMO | Thermo Fisher Scientific Inc | 15.00% | -100.10% |
| SHC | Sotera Health Company | 9.49% | -100.07% |
| DGX | Quest Diagnostics Inc | 8.70% | -100.06% |
| LH | Laboratory Corp Of America Holdings | 7.85% | -100.05% |
| IQV | IQVIA Holdings Inc | 6.60% | -100.05% |
| FONR | Fonar Corp | 6.20% | -100.04% |
| RVTY | Revvity Inc | 5.73% | -100.04% |
| ICLR | Icon Plc | 2.78% | -100.02% |
| CDNA | Caredx Inc | 2.39% | -100.02% |